Anulex Technologies, Inc. Completes Patient Enrollment Phase of Post Market Study and Announces the Treatment of over 6,000 Patients with the Xclose(TM) Tissue Repair System
Published: Nov 10, 2009
MINNEAPOLIS--(BUSINESS WIRE)--Anulex Technologies, Inc., a privately held medical device manufacturer focusing on spinal disc Preservation & Anular RepairTM products, announced the completion of the patient enrollment phase of its XcloseTM Tissue Repair System Post Market Clinical Study. 750 patients from 34 facilities around the U.S. were enrolled in the study. These patients will be followed for a two year period.